+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis



A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis



Medgenmed 8(4): 8



Atopic dermatitis (AD) is a common childhood disease that can disrupt the lives of patients and their families and, in turn, affect their quality of life. The goal of treatment is the long-term control of AD by minimizing the frequency and severity of flares. Topical corticosteroids of various potencies have been the mainstay of pharmacologic treatment of AD flares. In the past few years, the introduction of topical calcineurin inhibitors (TCIs) has provided physicians with an effective, well-tolerated alternative to topical corticosteroids. In January 2006, a boxed warning and a patient medication guide were added to TCI product labels in the United States after the US Food and Drug Administration raised concerns about their safety. These concerns were based on rare cases of skin malignancy and lymphoma, and a theoretical risk stemming from the systemic use of calcineurin inhibitors in animal studies and transplant patients. However, the boxed warning states that no causal link has been established between TCI use and malignancy. Pharmacokinetic studies have also shown that treatment with TCIs leads to only minimal systemic absorption. In addition, controlled, blinded studies have found no evidence of systemic immunosuppression and no causal relationship between the use of TCIs and the occurrence of lymphoma or other malignancies. Overall, TCIs have been shown to be an effective and valuable treatment option for AD.

(PDF emailed within 1 workday: $29.90)

Accession: 051247043

Download citation: RISBibTeXText

PMID: 17415290


Related references

Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. PharmacoTherapy 27(7): 1020-1028, 2007

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211(2): 174-187, 2005

Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology 6(2): 65-77, 2005

Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues. Journal der Deutschen Dermatologischen Gesellschaft 10(3): 167-172, 2013

Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Current Allergy and Asthma Reports 6(4): 270-274, 2006

Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. Bmc Pediatrics 16: 75, 2017

Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. American Journal of Therapeutics 16(3): 264-273, 2009

Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Current Medical Research and Opinion 24(4): 985-994, 2008

Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis 26(3): 122-132, 2016

CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy, Asthma, and Clinical Immunology 9(1): 24-24, 2013

The treatment of atopic dermatitis in adults with topical calcineurin inhibitors. Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 54(5): 424-431, 2003

Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatric Drugs 15(4): 303-310, 2013

Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis. American Journal of Clinical Dermatology 7(4): 213-222, 2006

Calcineurin inhibitors in treatment of atopic dermatitis. Topical corticoids now only in severe outbreaks?. Mmw Fortschritte der Medizin 145(29-30): 62-62, 2003

Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence. American Journal of Clinical Dermatology 5(4): 267-279, 2004